Cargando…

S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells

BACKGROUND: Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. The objective of our study was to find candidate protein markers for tumor sensitivity to L-OHP from intracellular proteins of human colorectal cancer (CRC) cell lines. We performed expression difference...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Sayo, Yamayoshi, Yasuko, Nishimuta, Akito, Tanigawara, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317844/ https://www.ncbi.nlm.nih.gov/pubmed/22206547 http://dx.doi.org/10.1186/1477-5956-9-76

Ejemplares similares

Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells
por: Suzuki, Sayo, et al.
Publicado: (2014)

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
por: Yamada, Y, et al.
Publicado: (2008)

Quercetin-Induced Glutathione Depletion Sensitizes Colorectal Cancer Cells to Oxaliplatin
por: Lee, Jinkyung, et al.
Publicado: (2023)

Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer
por: Xu, Zongbin, et al.
Publicado: (2016)

Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24
por: Xi, Jingle, et al.
Publicado: (2018)

Adenovirus and Oxaliplatin cooperate as agnostic sensitizers for immunogenic cell death in colorectal carcinoma
por: Jessup, J. Milburn, et al.
Publicado: (2019)

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer
por: Zhang, Bo, et al.
Publicado: (2021)

WBSCR22 confers oxaliplatin resistance in human colorectal cancer
por: Yan, Dongmei, et al.
Publicado: (2017)

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer
por: Park, Sun Young, et al.
Publicado: (2022)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Role of oxaliplatin in the treatment of colorectal cancer
por: Comella, Pasquale, et al.
Publicado: (2009)

Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin
por: Wang, Qi, et al.
Publicado: (2019)

Role of S100 Proteins in Colorectal Carcinogenesis
por: Moravkova, Paula, et al.
Publicado: (2016)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins
por: LIU, YONGPING, et al.
Publicado: (2015)

Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1
por: Ge, Tingrui, et al.
Publicado: (2020)

RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
por: Morinaka, Takashi, et al.
Publicado: (2023)

Licochalcone H Targets EGFR and AKT to Suppress the Growth of Oxaliplatin -Sensitive and -Resistant Colorectal Cancer Cells
por: Lee, Seung-On, et al.
Publicado: (2023)

Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin-resistant cell line to oxaliplatin by inhibiting excision repair cross-complementing group 1 protein expression
por: Li, Ji-Min, et al.
Publicado: (2019)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
por: Sun, Wei, et al.
Publicado: (2021)

Commitment of Scaffold Proteins in the Onco-Biology of Human Colorectal Cancer and Liver Metastases after Oxaliplatin-Based Chemotherapy
por: Rotoli, Deborah, et al.
Publicado: (2017)

Regulation of S100A10 Gene Expression
por: Głowacka, Aleksandra, et al.
Publicado: (2021)

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells
por: Wen, Qiaocheng, et al.
Publicado: (2017)

Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
por: Kono, Toru, et al.
Publicado: (2011)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
por: Choi, Ji Hoon, et al.
Publicado: (2014)

Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer
por: Shuwen, Han, et al.
Publicado: (2022)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
por: Chocry, Mathieu, et al.
Publicado: (2022)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Phenoxodiol sensitizes metastatic colorectal cancer cells to 5-fluorouracil- and oxaliplatin-induced apoptosis through intrinsic pathway
por: Yaylaci, Esra, et al.
Publicado: (2020)

Overexpression of miR-106a enhances oxaliplatin sensitivity of colorectal cancer through regulation of FOXQ1
por: Liu, Zhihu, et al.
Publicado: (2020)

β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1
por: Li, Xiaoqiang, et al.
Publicado: (2016)

miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells
por: Tanaka, Shota, et al.
Publicado: (2021)

The prognostic value of S100A10 expression in cancer
por: Tantyo, Normastuti Adhini, et al.
Publicado: (2019)

Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression
por: Wen, Shuangshuang, et al.
Publicado: (2016)

FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression
por: Tong, Jiafeng, et al.
Publicado: (2019)

Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma
por: Han, Jiayi, et al.
Publicado: (2020)

MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer
por: Wang, Yao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbv9k21sk7ru6rdvhthekdp2ji